Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.77
-5.1%
$0.83
$0.70
$1.65
$59.84M2.06361,665 shs282,299 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$10.39
+6.8%
$12.64
$8.50
$23.00
$64.96MN/A37,647 shs3,867 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.22
-6.9%
$3.23
$2.57
$6.88
$19.90M0.639,134 shs25,168 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$1.97
-3.9%
$2.30
$1.90
$4.21
$57.44M0.7176,284 shs222,345 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%-8.31%-1.28%-18.95%-36.36%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+6.83%+13.55%-25.79%+4.00%+1,038,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.72%-4.17%-8.00%-49.61%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%-1.50%-22.75%-23.94%-39.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.8075 of 5 stars
3.53.00.00.02.20.00.0
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8448 of 5 stars
0.03.00.00.02.21.70.6
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
2.0122 of 5 stars
0.05.00.00.02.41.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3.00
Buy$4.75516.88% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NAII, CLSD, IZTC, and VTGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/23/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
5/15/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
4/8/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/31/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.66M36.05N/AN/A($0.51) per share-1.51
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.17N/AN/A$13.32 per share0.24
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K117.24N/AN/A$2.44 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest NAII, CLSD, IZTC, and VTGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/14/2025Q1 2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.19
3.19
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3077.71 million72.89 millionOptionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance
Equities Analysts Set Expectations for VTGN Q1 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

$0.77 -0.04 (-5.06%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.02 (+1.95%)
As of 06/27/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$10.39 +0.66 (+6.83%)
As of 06/27/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.25 -0.21 (-6.07%)
As of 06/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$1.97 -0.08 (-3.90%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.02 +0.05 (+2.79%)
As of 06/27/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.